Optogenetic AAV Gene Therapy With Red-Shifted Light Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for retinal degenerative diseases like age-related macular degeneration (AMD) and retinitis pigmentosa (RP) are limited, and existing gene therapies are not applicable to the majority of patients due to genetic heterogeneity, while optogenetic approaches face limitations such as requiring bright light and phototoxic effects.
Innovation Solution
Administration of an adeno-associated viral (AAV) vector encoding an optogenetic fusion protein, which is delivered intravitreally, combined with neurally coded light stimulation, to enhance light sensitivity and restore vision by mimicking normal retinal function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If optogenetic approaches are used to treat retinal degenerative diseases, then a broader range of patients can obtain benefit independent of underlying gene defects, but the therapy requires very bright light to activate the protein and causes phototoxic effects
Solution Approach 1:
The patent changes the spectral parameters of light activation by using red-shifted optogenetic proteins (Chrimson, ReaChR, ChroME) that activate with longer wavelength light (590-630 nm) compared to traditional blue-light activated proteins. This parameter change reduces phototoxicity while maintaining therapeutic effectiveness
Solution Approach 2:
The patent employs composite optogenetic fusion proteins that combine light-sensitive ion channel domains with cellular targeting domains (such as synaptotagmin-1 for photoreceptor targeting or GFP variants for visualization). These composite structures enable selective expression in specific retinal cell types while reducing off-target phototoxic effects
2Illumination intensity
If traditional optogenetic proteins are used, then light sensitivity can be restored, but very bright light is required to activate the protein
Solution Approach 1:
The patent modifies the activation threshold parameter by engineering optogenetic proteins with altered spectral sensitivity. Red-shifted variants like ChroME and ReaChR require lower intensity light at their optimal wavelengths compared to traditional blue-light activated proteins, reducing the energy burden while restoring light sensitivity
3Reliability
If targeted gene therapy is used for RPE65 mutations, then specific patients can be treated, but the therapy is not applicable to the majority of patients with genetically heterogeneous retinal degeneration
Solution Approach 1:
The patent creates a universal optogenetic therapy platform that can be applied across multiple genetic causes of retinal degeneration. By targeting downstream retinal neurons (ganglion cells, bipolar cells) rather than specific photoreceptor genes, the therapy provides a multi-functional solution that works regardless of the upstream genetic defect causing photoreceptor loss
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy provides unprecedented vision restoration to patients with advanced stage blindness, enabling them to detect light, shapes, motion, and colors, with improved light sensitivity and tolerance in human patients.
Implementation Method 1
Administration of an adeno-associated viral (AAV) vector encoding an optogenetic fusion protein, which is delivered intravitreally
Implementation Method 2
a gene that expresses an optogenetic fusion protein... enabling them to detect light, shapes, motion, and colors
Data Source
AI summary
Provided herein is an AAV2 vector encoding SEQ ID NO: 4 as the optogenetic protein, and methods of use for e.g., retinitis pigmentosa.